This extended protocol adds intermediate dose steps (0.5mg, 3mg, 6mg) that do not appear in the standard clinical trial schedule
For example, US distributor McKesson reported an incredible $14 billion in GLP-1 revenue in a single quarter, yet they earn a mere 1-2% fee-for-service
There is no clinical evidence that tirzepatide compounded with B12 causes more or less heartburn than standard tirzepatide
The preclinical case for GLP-1s in opioid use disorder rests on the same reward-circuit argument
These questions represent the frontier of knowledge, and the answers, when they come, will refine the prevention and treatment strategies outlined in this guide
can help explain why these medications are transforming obesity treatment and metabolic health